Last updated: June 24, 2026
- Claims covering specific SMO inhibitors (and sometimes salt forms).
- Usually anchored by early priority dates from medicinal chemistry filings.
Solid-state IP: polymorphs and crystalline forms
- New crystalline forms, solvates, hydrates.
- Stability claims tied to storage conditions.
- These patents can remain active after “same molecule” composition patents near expiration.
Formulation and delivery system patents
- Tablet compositions with specific excipient systems.
- Coating, particle size distributions, and manufacturing process constraints.
- Oral bioavailability and dissolution profile claims.
Method-of-use patents
- Indication-specific dosing regimens and combinations.
- Patient selection criteria (disease stage/risk category).
- Sometimes claims on reduced dosing schedules for tolerability.
Manufacturing and process patents
- Process steps that create a particular solid form or ensure consistent particle characteristics.
- These can create non-infringement leverage for generics but raise development burden.
Common claim targets in SMO inhibitor “second-wave” litigation
- “Specific solid form” (Form X polymorph, crystal habit, or solvate)
- “Stable composition” with specified moisture content and storage constraints
- “Treatment of advanced BCC” with a defined dose and cycle
- “Treatment of hematologic malignancies” in defined risk buckets (for glasdegib)
How does exclusivity work for Hedgehog pathway inhibitors: Hatch-Waxman vs orphan vs pediatric?
Answer: Exclusivity is layered. For most L01XJ SMO inhibitors the market-access pathway hinges on patent terms plus exclusivity categories (orphan drug, new chemical entity, method-of-treatment exclusivity, pediatric extensions), then secondary patents influence “time-to-launch.”
Exclusivity stack mechanics that matter for L01XJ
| Exclusivity type |
What triggers it |
Practical impact on entry |
| Orphan drug exclusivity |
Orphan designation + approval |
Blocks generic competition even if some patents are weak or early |
| NCE (5-year) |
New active ingredient |
Delays ANDA filing to the timing boundary unless there is a carve-out |
| 3-year exclusivity (new clinical investigations) |
Substantial new clinical data |
Often slows label-driven competitive entries |
| Patent term adjustment (PTA) / pediatric extension (PTE) |
FDA regulatory timing |
Extends key patents beyond raw filing dates |
| “Non-patent” regulatory exclusivity |
Depends on approval history |
Can complicate conversion to generic labeling |
What delays generic launches even after primary patents expire
For SMO inhibitors, the bottleneck often becomes:
- a still-active polymorph/formulation patent that generics must “design around,” and
- method-of-use patents that keep certain label claims protected.
When do Hedgehog pathway inhibitors lose exclusivity and patent protection?
Answer: Exact expiration timing is asset-specific and depends on priority/filing dates, PTA/PTE, and whether secondary patents remain in force. In L01XJ, the “first expiration date” rarely equals the “first generic launch date” due to formulation and method-of-use fences.
Timeline framework to model entry risk
Use a two-step calendar per asset:
- Earliest independent patent expiration (usually composition core)
- Last blocking patent affecting either:
- the generic product’s solid form/formulation claims, or
- the label’s method-of-use claims for key indications.
Practical market consequence
Even after composition-of-matter expires, competition can remain absent where:
- the innovator’s marketed product uses a solid form still protected, or
- the FDA-approved labeling is entangled with method claims not carved out for the generic applicant.
What Orange Book status applies to SMO inhibitors in L01XJ?
Answer: Orange Book status is the entry map for ANDAs. For L01XJ, the Orange Book listings typically include multiple patents tied to the innovator product, often spanning composition, formulation, and use.
How to interpret Orange Book listings for L01XJ
- If multiple patents are listed, launch typically requires either:
- patent expiry,
- a successful Paragraph IV (or settlement),
- or label carve-out that avoids protected indications/dosing.
Typical Orange Book pattern for SMO inhibitors
- Several patents expiring earlier for composition coverage
- Later-expiring formulation and method patents that define “carve-out feasibility”
What is the Paragraph IV and generic entry risk for Hedgehog pathway inhibitors?
Answer: The generic entry risk is highest around the window when:
- core composition patents approach expiration, and
- the Orange Book shows later-expiring secondary patents that create strong incentives for settlement.
Common Paragraph IV outcomes in this therapeutic class
- Patent settlements that convert a potential Paragraph IV launch to a delayed entry date, often with:
- covenant-not-to-sue,
- defined “skinny label” permissions,
- and sometimes agreed launch at a specific date.
- Multi-patent litigation where each asserted patent covers a different infringement theory (solid form, formulation, use).
What drives settlement likelihood in L01XJ
- SMEs and generics face higher development and compliance costs due to:
- controlled solid form requirements,
- narrow dissolution and stability specifications for oral agents,
- and the need to address method-of-use label protection.
How strong is the patent estate for vismodegib, sonidegib, and glasdegib?
Answer: Patent estate strength in L01XJ is generally high for three reasons: (1) secondary patent density, (2) broad label protections built from method-of-use claims, and (3) solid-state/formulation fences that are harder to design around than simple molecular analogs.
Strength indicators used in L01XJ deals and litigation posture
- High count of Orange Book patents per product
- Broad claim families covering:
- solid forms and manufacturing routes
- patient populations and dosing regimens
- Evidence of sustained enforcement:
- recurring litigation or frequent “settlement-to-launch” outcomes
What formulations are protected for Hedgehog pathway inhibitors?
Answer: For SMO inhibitors, formulation protection often targets:
- specific tablet composition ratios,
- moisture control and stability,
- particle size and dissolution profiles,
- and manufacturing processes that yield the protected solid form.
Formulation patent themes that create generic barriers
| Barrier theme |
Why it matters |
Typical generic response |
| Polymorph-controlled manufacturing |
Innovator claims a particular crystalline form |
Redesign solid form or demonstrate non-infringement on solid-state parameters |
| Stability and storage constraints |
Claims may specify moisture limits and storage conditions |
Reformulate under different excipient/processing design space |
| Dissolution profile claims |
Claims can require target dissolution curves |
Adjust particle size or excipients to match target profile without infringing |
| Method-of-use linked to tolerability |
Dosing regimens can be claimed |
Seek skinny label for non-protected regimens |
What method-of-use patents cover hedgehog pathway inhibitors?
Answer: Method-of-use protection commonly covers:
- advanced or metastatic disease settings,
- specific basel cell carcinoma subtypes/stages,
- and in hematologic indications, disease-risk categories and lines of therapy.
Method-of-use claim “attack surface”
- If a competitor can carve out an indication or specific dosing regimens, it can launch earlier with a narrow label.
- If method-of-use claims track the innovator’s exact labeling, launch is delayed until those patents expire.
Which companies are challenging L01XJ hedgehog patents via ANDA or Paragraph IV?
Answer: The challenge landscape in L01XJ typically includes multiple generic manufacturers as well as specialty generics for oncology assets. The core determinant of which players participate is the ability to mount a credible design-around for solid-state/formulation IP.
Competitive pattern (how challenger selection is shaped)
- Strongest challengers for L01XJ typically have:
- solid-form development capability,
- controlled manufacturing experience,
- and portfolio budgets for multi-patent litigation.
What patent litigation affects market entry for Hedgehog pathway inhibitors?
Answer: L01XJ litigation tends to center on:
- Orange Book patents tied to solid forms/formulations,
- indication-specific method-of-use patents,
- and settlement frameworks that define a delayed generic launch date.
Litigation-to-market translation
- A successful Paragraph IV often still triggers delayed entry due to:
- appeal cycles,
- preliminary injunction outcomes,
- and settlement terms.
What licensing deals or settlements shape the launch calendar for SMO inhibitors?
Answer: For L01XJ, settlements are the dominant mechanism that converts a contested ANDA path into scheduled launches.
Settlement terms typically observed in this class
- Launch date tied to a specific patent expiration
- License scope limited to:
- a skinny label
- or a defined formulation that avoids certain infringement theories
- Covenant-not-to-sue for the settlement product under specified manufacturing conditions
How do biosimilar risks apply to L01XJ Hedgehog inhibitors?
Answer: Biosimilar risk is not a material factor because L01XJ hedgehog inhibitors are small molecules targeting SMO, not biologics.
Implication for investors and litigators
- Competition risk is mainly generic/derivative small-molecule entry rather than biosimilar substitution.
How does L01XJ compare with other oncology pathway classes on patent density?
Answer: Hedgehog SMO inhibitors show higher-than-average post-core patent density due to:
- solid-state/formulation and stability patents,
- method-of-use claims tied to specific oncology settings.
Competitive implication
Generic timelines are typically dominated by:
- patent fences on product form and labeling, not just composition expiration.
Key Takeaways
- L01XJ Hedgehog inhibitors are SMO small molecules concentrated in vismodegib, sonidegib, and glasdegib, with market entry governed by dense patent estates rather than molecule-level expiry alone.
- Patent strength is driven by secondary layers: polymorph/crystal form, oral formulation stability/dissolution, and indication-specific method-of-use claims.
- Exclusivity and Orange Book status jointly control launch timing. Even when composition patents expire, later-expiring formulation or method-of-use patents can keep “real-world generic entry” delayed.
- Paragraph IV and litigation risk is high near expiration windows, and settlement calendars often determine the effective launch date more than court outcomes.
- Biosimilar risk is not applicable for these assets; the competitive battlefield is ANDA-style generics, specialty generics, and design-around strategies.
FAQs
- Which patents typically block generic entry for vismodegib or sonidegib even after composition expiration?
- How do polymorph and solvate patents affect the ability to launch an ANDA for SMO inhibitors?
- What label carve-outs are usually used in skinny-label settlement strategies for Hedgehog pathway drugs?
- What exclusivity categories most often delay ANDA submissions for oncology small molecules like SMO inhibitors?
- How do manufacturing process patents for specific solid-state forms influence infringement analysis for generic products?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. United States Food and Drug Administration.
- FDA. Hatch-Waxman: Drug Patent Expiration and Application Submission. United States Food and Drug Administration.
- FDA. Orphan Drug Designations and Approvals. United States Food and Drug Administration.
- U.S. Code. 35 U.S.C. § 156 (Patent term adjustments).
- U.S. Code. 35 U.S.C. § 271 (Infringement of patent rights).
